Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 8.2% - Here's What Happened

Key Points

• Shares rose 8.2% to as high as $14.04 (last $13.84) on Monday, though trading volume was light at about 437,609 shares, down 78% from the average session.
• Quarterly results beat expectations: ADPT reported ($0.09) EPS vs. a ($0.19) consensus and revenue of $71.68M (vs. $59.38M), a 51% YoY revenue increase, but the company remains unprofitable with negative net margin and ROE.
• Analyst sentiment is cautiously positive — a "Moderate Buy" consensus with an average price target of $18.25, and several firms (including Guggenheim and Piper Sandler) setting $21 targets.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) shares shot up 8.2% during trading on Monday . The stock traded as high as $14.04 and last traded at $13.8360. 437,609 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 2,033,126 shares. The stock had previously closed at $12.79.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ADPT. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Finally, TD Cowen reiterated a "buy" rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Adaptive Biotechnologies has a consensus rating of "Moderate Buy" and an average price target of $18.25.

Adaptive Biotechnologies Stock Performance

The company has a market capitalization of $2.19 billion, a price-to-earnings ratio of -35.40 and a beta of 2.29. The firm's 50-day simple moving average is $14.95 and its 200-day simple moving average is $15.99.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business's quarterly revenue was up 51.0% on a year-over-year basis. During the same period last year, the business posted ($0.23) EPS. Equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Insider Activity at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 10,000 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $14.85, for a total transaction of $148,500.00. Following the sale, the insider directly owned 1,512,058 shares in the company, valued at approximately $22,454,061.30. The trade was a 0.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total transaction of $458,855.03. Following the sale, the chief operating officer owned 434,188 shares in the company, valued at approximately $6,439,008.04. This trade represents a 6.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 2,422,761 shares of company stock valued at $34,994,005. Company insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC boosted its position in Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company's stock valued at $2,265,000 after buying an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company's stock valued at $511,000 after buying an additional 2,914 shares in the last quarter. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies in the first quarter valued at about $93,000. New York State Common Retirement Fund boosted its position in Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company's stock valued at $551,000 after buying an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company's stock worth $4,417,000 after purchasing an additional 333,379 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.